Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
July 30, 2020
2 min read
Save

Methotrexate does not increase risk for rheumatoid arthritis-associated ILD

Source/Disclosures
Disclosures: The authors report no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Methotrexate use by patients with rheumatoid arthritis was not associated with an increased risk for developing interstitial lung disease, according to a study published in European Respiratory Journal.

“Methotrexate is recommended as the first-line treatment of rheumatoid arthritis as it effectively reduces disease activity, morbidity and mortality,” Pierre-Antoine Juge, MD, rheumatologist in the department of rheumatology at Bichat-Claude Bernard Hospital, Paris, and colleagues wrote. “Methotrexate has long been suspected as a causative agent in lung disease, including fibrotic ILD and many rheumatologists and pneumologists are reluctant at introducing or maintaining methotrexate in patients with rheumatoid arthritis-ILD.”

Image of arthritic hand
Source: Adobe Stock.

Researchers conducted a case-control study of 410 patients with chronic fibrotic ILD associated with rheumatoid arthritis (RA) and 673 patients with RA who did not have ILD. The researchers assessed methotrexate exposure via a systematic chart review of all patients. Patients were assigned to different samples and estimates were pooled over the samples using meta-analysis.

In the discovery sample, which included 100 patients with RA-ILD and 165 patients with RA without ILD, 60% of those with RA-ILD and 83% with RA and no ILD had used methotrexate. The researchers reported a negative association between methotrexate use and RA-ILD after controlling for age, sex, smoking status, methotrexate exposure duration, length of methotrexate use at RA onset and biologic use (adjusted OR = 0.46; 95% CI, 0.24-0.9; P = .022). In the pooled replication sample, which included 310 patients with RA-ILD and 508 patients with RA without ILD, the researchers found a similar association, with fewer methotrexate users among those with RA-ILD compared with those with RA and no ILD (79.7% vs. 95.5%; aOR = 0.39; 95% CI, 0.19-0.79; P = .009).

In the combined population of both samples, the researchers reported an inverse relationship between methotrexate ever use and ILD occurrence among patients with RA (aOR = 0.43; 95% CI, 0.26-0.69; P = .0006). Methotrexate ever users were less frequent among the population of patients with RA-ILD compared with those without ILD.

ILD detection was delayed among ever users in patients with RA-ILD compared with never users (P < .001).

“These results suggest that methotrexate could be considered as having a disease-modifying effect on RA-ILD that could result from distinct anti-inflammatory mechanisms. ... We acknowledge that a prospective study would be required to further establish that methotrexate ever use is delaying the onset of RA-ILD, such a trial is unlikely to be performed due to the central role of methotrexate in the management of RA,” the researchers wrote.